[go: up one dir, main page]

WO2008035152A1 - Procédé cosmétique permettant de faire disparaître les cernes - Google Patents

Procédé cosmétique permettant de faire disparaître les cernes Download PDF

Info

Publication number
WO2008035152A1
WO2008035152A1 PCT/IB2007/001986 IB2007001986W WO2008035152A1 WO 2008035152 A1 WO2008035152 A1 WO 2008035152A1 IB 2007001986 W IB2007001986 W IB 2007001986W WO 2008035152 A1 WO2008035152 A1 WO 2008035152A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
suhr
dark
application
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001986
Other languages
English (en)
Inventor
Carlo Ghisalberti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008035152A1 publication Critical patent/WO2008035152A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51—Chelating agents

Definitions

  • the purplish-dark colour are related with the tiny microcapillaries and with a poor and/or defective circulation, being triggered by factors such as stress, lack of sleep, and so on.
  • a common thought is that the thin skin of lower eyelids makes the veins underneath and the darker shadows of bone to show through. Actually, skin gets thinner with age due to break down of the "scaffolding" formed by collagen fibres and the weakening of elastic fibres which keep the skin taut.
  • the invention refers to a cosmetic method to remove the undereyes hemosiderinic depots, which comprise the screening of one or more "Selective Undereye Hemosiderin Remover(s)" ("SUHR”), the preparation of a cosmetic composition, and its application onto the periocular area.
  • SUHR Selective Undereye Hemosiderin Remover
  • the criteria to make a chelating agent elegible for SUHR include high affinity and specificity for Fe 3+ , good skin bioavailability and/or disposition kinetic of the formed complex, and safe use, i.e. non-sensitization and non-irritanting properties.
  • the invention is directed to a cosmetic method to treat dark undereye marks.
  • the efficient method to remove the undereyes hemosiderinic depots on a subject with dark undereye circles comprises: a) identification of safe and effective agent(s) based on selectivity, affinity, and local bioailability along with and safety for the use on the periocular area; herewith named "Selective Undereye Hemosiderin Remover(s)" ("SUHR"); b) preparation of a cosmetic composition comprising SUHR; and c) local application of said compositions to a subject with dark undereye circles.
  • SUHR Selective Undereye Hemosiderin Remover
  • the screening of SUHR is fundamental in order to design a cosmetic composition which is fully effective for the cosmetic target, while also being safe in the periocular application.
  • the selection of SUHR suitable for the purpose is therefore based on the matching of critical parameters for efficacy and safety (tolerability) which would be otherwise encountered.
  • step (a) is primary construed with in vitro assays, which are shown herewith after.
  • the summarized criterium is: pFe 3+ > 16, preferably > 20.
  • Bioavailability Another condition is the skin bioavailability, for the efficacy of SUHR is also related to the contact with the hemosiderinic iron as well as to the capacity to exctreted it from the skin layer after the complex is formed.
  • the parameter #3 is a composed factor which express the local bioavailability, wich has been herewith defined as "modified Veber rule".
  • a SUHR and the composition comprising thereof are their suitability for the use in contact with periocular skin and, occasionally, to the eyes without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • AOI % [OD SUHR / ODnegative co ntrol] x 100 > 40%, preferably > 60%; and sensitization expressed as MSC ⁇ 1 mg/ml, preferably ⁇ 100 microg/ml.
  • the SUHR can be formulated in cosmetic composition to be applied in the periocular area, said composition may be produced by know technics.
  • the concentration of SUHR on the cosmetic composition according to the invention depends on their class, as specified in the Example session.
  • composition of the invention may be in any cosmetical/galenical form normally used for periocular application, especially in the form of aqueous, hydroalcoholic or oily solution, aqueous or oily gel, liquid, paste or solid anhydrous product, dispersion of oil in aqueous phase in the presence of spherules, nanoparticles (nanospheres, nanocapsules or ionic and/or nonionic type lipid vesicles), direct (O/W), inverse (W/O) or multiple (0/W/O and W/O/W) emulsion.
  • the composition used according to the invention is preferably in the form of an aqueous gel or an OAV emulsion.
  • this composition may be more or less fluid and have the appearance of a white or coloured cream, a milk, a lotion, a serum, a paste or a foam. It may possibly be applied in the form of an aerosol, or in solid form, and for example in stick or compact product form. It may be used as a skin care and/or make-up product, for example as a foundation.
  • the aqueous phase may contain mostly water and may also comprise a mixture of water and a water-miscible organic solvent, i.e. having a miscibility in water greater than 50% w/w at 25°C.
  • the aqueous phase may typically be present in an amount greater than or equal to 10%, preferably 30%, even more preferably 50%, or even 70% w/w relative to the total weight of the composition.
  • the composition of the invention may also contain adjuvants common in the cosmetic field, such as hydrophilic or lipophilic gelling agents an active agents, preservatives, antioxidants, solvents, fragrances, fillers, sunscreens, pigments, odour absorbers and dyes.
  • the quantities of these various adjuvants are those conventionally used in the field under consideration, and, for example, are from
  • compositions 0.01 to 20% by total weight of the composition.
  • adjuvants depending on their nature, may be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and/or into the nanoparticles.
  • the proportion of the fatty phase may range from 5 to 80% w/w, and preferably from 5 to 50% w/w.
  • the fatty substances, the emulsifiers used in the emulsion composition are chosen from those conventionally used in the field under consideration.
  • the emulsif ⁇ er are preferably present, in the composition, in a proportion ranging from 0.3 to 30% w/w, and preferably from 0.5 to 20% w/w of the composition.
  • mineral oils liquid petroleum, isoparaffines
  • oils of plant origin avocado oil, soybean oil
  • oils of animal origin lanolin
  • synthetic oils perhydrosqualene
  • silicone oils cyclomethicone
  • fluorinated oils perfluoropolyethers
  • emulsifiers that can be used in the invention, mention may be made of, for example, fatty acid esters and polyethylene glycol esters such as PEG-50 stearate, and fatty acid esters and polyol esters such as glyceryl stearate and sorbitan tristearate.
  • hydrophilic gelling agents mention may be made of, in particular, carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate/alkylacrylates copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
  • compositions according to the invention may comprise as additional active agents at least one compound chosen from: desquamating and/or hydrating agents; depigmenting agents; agents for stimulating the proliferation of fibroblasts; keratinocytes and/or differentiation stimulators; matrix metalloproterases (MMP) inhibitors; skin macromolecule promoters; muscle relaxants; anti-radicals and antiglycating agents; vasoprotective compounds; and mixtures thereof.
  • MMP matrix metalloproterases
  • retinol and its derivatives such as retinyl palmitate; ascorbic acid and its derivatives such as magnesium ascorbyl phosphate and ascorbyl glucoside; tocopherol and its derivatives such as tocopheryl acetate; nicotinic acid and its precursors such as nicotinamide; ubiquinone; glutathion and its precursors such as L-2-oxothiazolidine-4-carboxylic acid; plant extracts and especially olive leaf extracts, and also the plant proteins and their hydrolysates such as rice or soybean protein hydrolysates; algal extracts and in particular laminaria extracts; bacterial extracts; sapogenins such as diosgenin and Dioscorea extracts, in particular wild yam extracts; ⁇ -hydroxy acids; ⁇ -hydroxy acids e.g salicylic acid and 5-n-octanoylsalicylic acid; oligopeptides and pseudodipeptides and
  • composition according to the invention is applied as external formulations either by the subject itself or by a praticioner, cosmetologist, or esthetician.
  • compositions may comprise a percutaneous penetration enhancer that augments delivery of active ingredient to the dermal layers.
  • a percutaneous penetration enhancer that augments delivery of active ingredient to the dermal layers.
  • Various compounds for enhancing the permeability of skin are known in the art and are described in the pertinent texts and literature.
  • Compounds enhancing the skin permeability include: sulfoxides such as dimethyl sulfoxide (DMSO) and decylmethylsulfoxide (ClOMSO); ethers such as diethylene glycol monoethyl ether (TranscutolTM) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80), and lecithin; 1 -substituted azacycloheptan-2- ones, particularly AzoneTM; alcohols such as
  • the book Percutaneous Penetration Enhancers provides an excellent overview of the field and further background information on percutaneous enhancers.
  • the application can be carried out by device tools with increase skin porosity and/or hydration, such as occlusion devices, hydrocolloid patches and other intradermal delivery systems, lipophilic penetrants including liposomes, microemulsions and lipospheres, electroporation, ultrasound, iontophoresis, and the like methods. More particularly, for such an intradermal route several tool can be applied, including local injection, e.g. syringe or dermojet, in the latter modes of application of SUHR will conveniently suspended in a sterilized liquid composition.
  • the method of application of the composition according to the invention should be at least once per day, even preferably repeated several times per day, such as in the range of 2 to 8 times per day, preferably 2-3 times per day, and continued for several days, preferably at least 3 to 5 weeks.
  • the affinity constant for the iron (IU) -SUHR interaction is determined by a spectrophotometric competition study as described in Plant Physiology, 2000, 124, 1149-57; and Inorg. Chem. 1988, 27, 4140-9.
  • the iron (III) complexes of the ligand [Fe 111 SUHR] 2 is prepared in a 10:1 ligand:iron molar ratio (total iron concentration 4.4 x 10 "5 M) in 0.1 m MOPS-KOH buffer, pH
  • Rlog ⁇ (Fe 3 +/zn2+) the ratio of cumulated stability constant of the complexes [SUHR- Fe 3+ ] and [SUHR-Zn 2+ ], which are indipendently calculated as described in Biological Trace Element Research, 1989, 21, 295. Parameter #3
  • the modified Veber rule (Veber DF et all.; J. Med. Chem. 2002, 45, 2615-23) is allow the provisional calculation of skin bioavailability by the following parameters:
  • H-boundtot is the total H-acceptor and donor bounds, calculated “by hand”, or with "Marvin View - Hydrogen Bond Donor-Acceptor (HBDA) Plugin” (ChemAxon).
  • logD Distribution coefficient, determind in octanol/MOPS (pH 7.4), or with the programs "ACD/logD Suite” (ACD Inc., Toronto, Canada) or ChemDBsoft Lite. Parameter #4
  • the irritation potential is misured by the viability of the candidate SUHR on human corneal epithelial (HCE) model (SkinEthic Laboratories, Nice, France) as described in Toxicology in Vitro, 2006, 20, 1 - 17.
  • HCE human corneal epithelial
  • a candidate SUHR is applied directly onto the surface of the epithelial culture for exposure periods (10, 20, 30 and 60 minutes) and the induced cytotoxicity is monitored as a decreased MTT metabolism relative to the negative (vehicle) control cultures.
  • the percentage viability (AOI %) is then calculated for each culture to identify the most relevant exposure time.
  • the sensitization potential is performed as described in Toxicol hi Vitro, 2001, 15, 4-5, 327-31 and in Contact Dermatitis 46, suppl. 4, 117.
  • Langerhans cells and immature dendritic cells are the model systems for screening of skin sensitizers are used to test the sensitizing potential of the candidate SUHR.
  • the test is carried out on a primary cell line of dendritic cells derived from human monocytes of healthy volunteers peripheral blood . Cells are kept in RPMI 1640, FCS (10%), GM-CSF (50 ng/ml) e IL-4 (1000 IU/ml) added. After the incubation with the tested substance and the controls, cells are collected, checked under the microscope for their vitality by staining with Trypan Blue dye and counting in a cell counter chamber, washed in PBS and then marked with a fluoresceinated anti-B7.1 or B7.2 antibody.
  • the MFI Magnetic Fluorescence Intensity linked to the cells was evaluated by means of a flux cytofluorimeter (FACS, Fluorescence Activated Cell Sorter, Becton Dickinson, Mountain View, CA). This value is proportional to the expression of costimulatory molecules.
  • FACS Fluorescence Activated Cell Sorter, Becton Dickinson, Mountain View, CA. This value is proportional to the expression of costimulatory molecules.
  • the MFI of untreated cells and treate cells with a monoclonal isotype- matched antibody is used as an internal control (basal fluorescence).
  • the minimum sensitization concentration (MSC) as the concentration which ellicit at least a 10% increase of CD80 and CD86 of dendritic cell expression.
  • Class "A” are ideal SUHR in terms of affinity, specificity, bioavailability, and (periocular) skin safety.
  • the compound belonging to this class can be applied in the composition of invention in amount from about 10% to about 0.5% w/w, preferably from about 5% to about 1% w/w.
  • Class "A” includes: 3-hydroxy-2-methyl-4-pyrone (maltol); 3-hydroxy-2-ethyl-4- pyrone (ethyl maltol); l-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(lH)-pyridone (octopirox); 6-cyclohexyl-l-hydroxy-4-methyl-2(lH)-pyridinone (ciclopirox); 6-[[p- chlorophenoxy)phenoxy]methyl]-lhydroxy-4-methyl-2(lH)-pyridone (rilopirox); 1 ,2-dimethyl-3-hydroxypyrid-4-one (deferiprone); 1 -methyl-2-ethyl-3-hydroxypyrid- 4-one; l,2-diethyl-3-hydroxypyrid-4-one; 2,6-pyridinedicarboxylic acid (dipicolinic acid); and salts thereof, particularly the ethanolamine (“olamine”) salts.
  • olamine ethanolamine
  • Class "B” are second choice SUHR due to limitations mainly referred to the safety, for their low specificity along with irritation/sensitization behaviour.
  • the compound belonging to this class can be applied in the composition of invention in amount from about 1% to about 0.05% w/w, preferably from about 0.5% to about 0.1% w/w.
  • Class “B” includes: gallic acid; gallic acid esters (e.g. propyl gallate, lauryl gallate), salicyl hydroxamic acid, decyl hydroxamic acid; 5-hydroxy-2-(hydroxymethyl)-4H- pyran-4-one (kojic acid); gentisic acid, methyl gentisate, mimosine, and the like.
  • Class "C” are low efficacy SUHR from a limited activity, particularly low specificity and local bioavailability, instead with a good profile in terms of safety.
  • the compound belonging to this class can be applied in the composition of invention in association to Class "A” compounds in various cosmetically acceptable amounts.
  • Class "C” includes: tartaric acid; citric acid; minotrimethylene phosphonic acid; ⁇ - alanine diacetic acid, EDTA; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; cyclohexanediaminetetracetic acid; oxalic acid and its esters; edetic acid; etidronic acid; HEDTA; aminotrimethylene phosphonate; pentetic acid; phyytic acid; nitrilotriacetic acid; and salt and derivatives thereof.
  • Class "D” are less recommended SUHR for they do not match one or more parameters of activity or safety.
  • the compound belonging to this class can be applied in the composition of invention in association to Class "A” and, optionally, "B” and/or “C” compounds in amount below 1% w/w, preferably below 0.1%.
  • Class "D" representative compounds include: 6-hydroxy-2-phenyl-3(2H)- pyridazinone; 2,3-dihydroxybenzoic acid; 4,5-dihydroxy-l,3-benzene-disulfonic acid; 2,3-dihydroxypyridine; 2,4,5-trihydroxypyrimidine; 2,3-dihydroxynaphthalene; and 4-(2-amino- 1 -hydroxyethyl)- 1 ,2-benzenediol; N-benzoyl-N-phenylhydroxylamine; 2,2'-dipyridylamine; 1,10-phenanthroline; 2,3-bis(2-pyridyl)pyrazine; 2,3-bis(2- pyridyl)-5,6-dihydropyrazine; 1,1 '-carbonyldiimidazole; 2,4-bis(5,6-diphenyl- 1,2,4- triazine-3-yl)pyridine; 2,4,6-tri(2-pyridyl
  • 100 g of gel contain: (g) Gomma xanthan 0.7
  • 100 g of emulsion contain: (g) Glycerin 2.0
  • Ciclomethicone (cyclopentadimethylsiloxane) 20
  • Abil WO9 mixture of PEO and PPO-cetyldimethylsiloxane, 3.0 4-polyglycerol isoglyceryl isostearate and hexyl laurate
  • PEO and PPO-cetyldimethylsiloxane 3.0 4-polyglycerol isoglyceryl isostearate and hexyl laurate
  • a commercial eye formulation can be additivated with a SUHR.
  • Said formulation is "Lierac Diopticerne Cr Occhiaie", originally comprising the following ingredients: Water (aqua), Elaeis Guineensis, Butcherbroom Extract, Carbomer, Triethanolamine, Arnica montana, Tocopheryl Acetate, Phenoxyethanol, Parabens.
  • Incremental Composition Example #2 A SUHR blend is added to "Rilastil Young Eye Contour Gel", originally comprising the following ingredients: Water, Glycerin, Glyceril Polyacrilate, Panthenol, Aloe Barbadensis, Sodium Hyaluronate, Prunus Africana, Saccharomyces Lysate, PEG-40, Hydrogenated Castor Oil, Arginine, Propylene Glycol, Phenoxyethanol, Imidazolidinyl Urea, Parabens, Disodium EDTA. Incremental Composition Example #3
  • a SUHR blend is added to "Lierac Dioptigel", originally comprising the following ingredients: Water, Alchemilla Vulgaris, Hedera Helix, Chamomilla Recutita, Equisetum Arvense, Carbomer, Tromethamine, Phenoxyethanol, Parabens.
  • "Lierac Dioptigel” originally comprising the following ingredients: Water, Alchemilla Vulgaris, Hedera Helix, Chamomilla Recutita, Equisetum Arvense, Carbomer, Tromethamine, Phenoxyethanol, Parabens.
  • the Composition Example #1 has been supplied to a female subject of 36 years of age and instructed to apply it the lower perioculare area regularly at least once a day for three weeks. During the treatment the regularization and the progressive disappearance of dark undereyes marks has been noticed. No intolerance phenomena were noticed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un procédé cosmétique pour le traitement des cernes. Ce procédé consiste à cribler un ou plusieurs agents chélateurs du fer spécifiques et sûrs. L'invention concerne également la préparation d'une composition cosmétique, et son application sur la surface de la cerne.
PCT/IB2007/001986 2006-09-18 2007-07-13 Procédé cosmétique permettant de faire disparaître les cernes Ceased WO2008035152A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20061770 ITMI20061770A1 (it) 2006-09-18 2006-09-18 Metodo cosmetico di riduzione delle occhiaie
ITMI2006A001770 2006-09-18

Publications (1)

Publication Number Publication Date
WO2008035152A1 true WO2008035152A1 (fr) 2008-03-27

Family

ID=38982593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001986 Ceased WO2008035152A1 (fr) 2006-09-18 2007-07-13 Procédé cosmétique permettant de faire disparaître les cernes

Country Status (2)

Country Link
IT (1) ITMI20061770A1 (fr)
WO (1) WO2008035152A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083582A1 (fr) * 2009-01-26 2010-07-29 Michael Spino Utilisation de défériprone pour le traitement et la prévention de troubles oculaires liés au fer
WO2013001192A1 (fr) 2011-06-30 2013-01-03 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux esters de dérivés N-acylés d'acides aminés et d'isosorbide, procédé pour leur préparation, et utilisation en cosmétique et comme médicament
WO2013060964A1 (fr) 2011-10-27 2013-05-02 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux esters de derives n-acyles d'acides amines et de diols, procede pour leur preparation, et utilisation en cosmetique et comme medicament
EP3195854A1 (fr) 2016-01-22 2017-07-26 Tomorrowlabs GmbH Traitement cosmetique de peau saine, en particulier peau mature

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762847A (en) * 1985-10-04 1988-08-09 Beecham Group P.L.C. Method of treating acne
CH674930A5 (fr) * 1987-07-17 1990-08-15 Oreal
WO1994002592A1 (fr) * 1992-07-24 1994-02-03 Celltech Limited Culture de cellules animales
WO1996002226A1 (fr) * 1994-07-20 1996-02-01 Pierre Fabre Dermo-Cosmetique Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
WO2003002119A1 (fr) * 2001-06-27 2003-01-09 Johnson & Johnson Medical Limited Traitement et prevention de la liposclerodermie
US20030049292A1 (en) * 1999-12-18 2003-03-13 Clariant Gmbh Hair treatments comprising zinc salts of piroctone olamine
WO2004024120A2 (fr) * 2002-09-11 2004-03-25 Gil Bianco Produits medicamenteux de nettoyage de peau
US20040132667A1 (en) * 2003-11-17 2004-07-08 Sederma S.A.S Compositions containing mixtures of tetrapeptides and tripeptides
US20050063903A1 (en) * 2003-02-06 2005-03-24 Zeligs Michael A. Combined use of cruciferous indoles and chelators for the treatment of papilloma virus-related conditions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762847A (en) * 1985-10-04 1988-08-09 Beecham Group P.L.C. Method of treating acne
CH674930A5 (fr) * 1987-07-17 1990-08-15 Oreal
WO1994002592A1 (fr) * 1992-07-24 1994-02-03 Celltech Limited Culture de cellules animales
WO1996002226A1 (fr) * 1994-07-20 1996-02-01 Pierre Fabre Dermo-Cosmetique Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
US20030049292A1 (en) * 1999-12-18 2003-03-13 Clariant Gmbh Hair treatments comprising zinc salts of piroctone olamine
WO2003002119A1 (fr) * 2001-06-27 2003-01-09 Johnson & Johnson Medical Limited Traitement et prevention de la liposclerodermie
WO2004024120A2 (fr) * 2002-09-11 2004-03-25 Gil Bianco Produits medicamenteux de nettoyage de peau
US20050063903A1 (en) * 2003-02-06 2005-03-24 Zeligs Michael A. Combined use of cruciferous indoles and chelators for the treatment of papilloma virus-related conditions
US20040132667A1 (en) * 2003-11-17 2004-07-08 Sederma S.A.S Compositions containing mixtures of tetrapeptides and tripeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. SINGH: "An overview of transdermal drug delivery", DRUG DELIVERY REPORT, 2005, XP002467537, Retrieved from the Internet <URL:http://www.drugdeliveryreport.com/articles/ddr_w2005_article06.pdf> *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083582A1 (fr) * 2009-01-26 2010-07-29 Michael Spino Utilisation de défériprone pour le traitement et la prévention de troubles oculaires liés au fer
WO2013001192A1 (fr) 2011-06-30 2013-01-03 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux esters de dérivés N-acylés d'acides aminés et d'isosorbide, procédé pour leur préparation, et utilisation en cosmétique et comme médicament
WO2013060964A1 (fr) 2011-10-27 2013-05-02 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux esters de derives n-acyles d'acides amines et de diols, procede pour leur preparation, et utilisation en cosmetique et comme medicament
US9567290B2 (en) 2011-10-27 2017-02-14 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Esters of N-acyl derivatives of amino acids and diols, method for preparing same, and use thereof in cosmetics and as a drug
EP3195854A1 (fr) 2016-01-22 2017-07-26 Tomorrowlabs GmbH Traitement cosmetique de peau saine, en particulier peau mature
WO2017125574A1 (fr) 2016-01-22 2017-07-27 Tomorrowlabs Gmbh Traitement cosmétique d'une peau saine, en particulier d'une peau âgée

Also Published As

Publication number Publication date
ITMI20061770A1 (it) 2008-03-19

Similar Documents

Publication Publication Date Title
CN103189043B (zh) 毛发护理组合物和用于改善毛发外观的方法
EP2632470B1 (fr) Compositions de soins personnels comprenant une pyrithione et un chélateur du fer
CN101511331A (zh) 可使毛发看上去更浓密且更丰厚的毛发护理组合物
US5219847A (en) Antipruritic composition
JPH05301811A (ja) 美白化粧料
US20020028254A1 (en) Manganese compositions for reducing/preventing skin wrinkles and fine lines
WO2008035152A1 (fr) Procédé cosmétique permettant de faire disparaître les cernes
CN109481370A (zh) 一种舒缓抗过敏抗刺激护肤组合物及其制备方法和应用
JPH09157153A (ja) 皮膚外用剤
JP2000016917A (ja) 美白化粧料
KR101039713B1 (ko) 화장품의 ｐＨ범위가 약산성으로 변하는 것을 화장품 색의 변화로 알 수 있게 하는 2제형 화장품 조성물 및 이를 이용한 화장품
CN111150699A (zh) 滢润玉颜霜
KR100348155B1 (ko) 자연산 상황버섯 추출물을 함유하는 발모제 조성물 및이의 제조방법
EP0914816A1 (fr) Compositions de soins du cuir chevelu
US20160220479A1 (en) Topical compounds containing adipose-derived hormones for the rejuvenation of skin
US20040047831A1 (en) Use of a cell extract of at least a plant of the family pontederiaceae as anti-pollution agent
EP1082095A1 (fr) Compositions pour la croissance des cheveux a base de n-oxydes de ketones, de thioesters, d&#39;amides ou d&#39;esters heterocycliques, et utilisation de ces compositions
JPS63211214A (ja) 養毛料
US20160235642A1 (en) Melanin Binding Agents for Targeted Topical Delivery
JP4577596B2 (ja) 育毛剤又は発毛剤及びその使用方法
JP2002121110A (ja) 化粧料
EP2746253A1 (fr) Nouveaux composés à propriétés d&#39;éclaircissement de la peau
JP6359527B2 (ja) ピリジンジカルボン酸エステル及びグルコースと脂肪酸とのエステルを含む組成物、方法及び使用
EP2367522A2 (fr) Methode et composition pour le blanchiment de la peau
JPH1112134A (ja) 頭部用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804607

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804607

Country of ref document: EP

Kind code of ref document: A1